uniQure announces analysis of six-year follow-up data for Glybera uniQure announced the full analysis of the six-year follow-up data for patients treated once with Glybera, uniQure's gene therapy product for the treatment of lipoprotein lipase deficiency. Glybera is approved in the EU as a treatment for LPLD, a potentially life-threatening, orphan metabolic disease that results in patients' inability to process fat in the blood after a meal. LPLD patients eligible for Glybera treatment suffer from reoccurring and often severe pancreatitis events leading to recurrent admissions to hospitals and intensive care units.
News For QURE From The Last 14 Days
Check below for free stories on QURE the last two weeks.